Clinical developments in the treatment of relapsed or relapsed and refractory multiple myeloma: impact of panobinostat, the first-in-class histone deacetylase inhibitor
about
Clinical developments in the treatment of relapsed or relapsed and refractory multiple myeloma: impact of panobinostat, the first-in-class histone deacetylase inhibitor
description
2016 nî lūn-bûn
@nan
2016 թուականին հրատարակուած գիտական յօդուած
@hyw
2016 թվականին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Clinical developments in the t ...... histone deacetylase inhibitor
@ast
Clinical developments in the t ...... histone deacetylase inhibitor
@en
Clinical developments in the t ...... histone deacetylase inhibitor
@nl
type
label
Clinical developments in the t ...... histone deacetylase inhibitor
@ast
Clinical developments in the t ...... histone deacetylase inhibitor
@en
Clinical developments in the t ...... histone deacetylase inhibitor
@nl
prefLabel
Clinical developments in the t ...... histone deacetylase inhibitor
@ast
Clinical developments in the t ...... histone deacetylase inhibitor
@en
Clinical developments in the t ...... histone deacetylase inhibitor
@nl
P2093
P2860
P3181
P356
P1476
Clinical developments in the t ...... histone deacetylase inhibitor
@en
P2093
Erika M Price
Kimberly A Redic
Shannon M Hough
P2860
P304
P3181
P356
10.2147/OTT.S87962
P407
P577
2016-01-01T00:00:00Z